Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data from the analysis further illustrates the significance of the AI-based digital pathology platform in revealing fibrosis regression in patients treated with Tropifexor (TXR) and its relation to steatosis (liver fat) reduction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tropifexor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2019
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LJN452 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2018
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tropifexor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2018
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tropifexor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2016
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
Details : LJN452 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2016
Lead Product(s) : Tropifexor
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LJN452 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Cirrhosis, Biliary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2015
Lead Product(s) : Tropifexor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
